Pulmonary pleomorphic carcinoma with pseudoprogression during nivolumab therapy and the usefulness of tumor markers: A case report

Autor:	Akihiro Yoshimura, Yoji Urata, Taisuke Tsuji, Shinsuke Shiotsu, Tatsuya Yuba, Chieko Takumi, Ryosuke Hamashima, Noriya Hiraoka
Rok vydání:	2018
Předmět:	nivolumab pulmonary pleomorphic carcinoma business.industry Pleural effusion Immune checkpoint inhibitors immune checkpoint inhibitor pseudoprogression Case Report Case Reports General Medicine Pleomorphic carcinoma medicine.disease 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis Cytokeratin 19 fragment tumor marker Cancer research Pulmonary metastasis Medicine 030212 general & internal medicine Nivolumab business Pseudoprogression Tumor marker
Zdroj:	Clinical Case Reports
ISSN:	2050-0904
DOI:	10.1002/ccr3.1627
Popis:	Key Clinical Message Pseudoprogression was reported as one of the unconventional responses during immune checkpoint inhibitor therapy. A 70‐year‐old man with pulmonary pleomorphic carcinoma received nivolumab therapy. Pleural effusion and pulmonary metastasis increased, however then shrank and serum cytokeratin 19 fragment levels decreased. Serum tumor marker might help to distinguish pseudoprogression.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::240be1661a4d6302c975a8adadf04843 https://doi.org/10.1002/ccr3.1627 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.